Assembly Biosciences Inc (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $45.04, for a total transaction of $45,040.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of Assembly Biosciences Inc (ASMB) traded down $0.53 on Wednesday, hitting $45.75. 96,668 shares of the company’s stock were exchanged, compared to its average volume of 113,750. The firm has a market cap of $902.28, a price-to-earnings ratio of -15.40 and a beta of 0.91. Assembly Biosciences Inc has a 52 week low of $11.89 and a 52 week high of $52.37.

A number of equities analysts have weighed in on the stock. ValuEngine lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. BidaskClub lowered shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, Jefferies Group assumed coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.67.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors acquired a new position in shares of Assembly Biosciences in the 2nd quarter valued at $161,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Assembly Biosciences during the 2nd quarter valued at $212,000. Wells Fargo & Company MN acquired a new position in shares of Assembly Biosciences during the 2nd quarter valued at $213,000. Finally, State of Wisconsin Investment Board acquired a new position in shares of Assembly Biosciences during the 2nd quarter valued at $227,000. Institutional investors own 62.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/william-r-ringo-sells-1000-shares-of-assembly-biosciences-inc-asmb-stock.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.